Evaluation of Growth Differentiation Factor 15 as an Early Biomarker of Anthracycline‐Induced Cardiotoxicity Using an Integrated PK / PD Model

Documenti analoghi

• Pharmacogenomic variation and sedation outcomes during early intensive care unit admission: A pragmatic study
  di: Moataz E. Mohamed, et al.
  Pubblicazione: (2024)
• In vitro PK/PD modeling of tyrosine kinase inhibitors in non‐small cell lung cancer cell lines
  di: Linda Wanika, et al.
  Pubblicazione: (2024)
• First‐In‐Human, Randomized, Placebo‐Controlled, SAD and MAD Trial to Evaluate Safety, Tolerability, and PK/PD Modeling of Potravitug in Healthy Adults
  di: Marcus May, et al.
  Pubblicazione: (2025)
• Translational PK–PD model for in vivo CAR‐T‐cell therapy delivered using CAR mRNA‐loaded polymeric nanoparticle vector
  di: Se Jin Kim, et al.
  Pubblicazione: (2024)
• A Randomized Phase 1 Study Comparing the PK , PD , Safety, and Immunogenicity of Proposed Biosimilar RGB ‐14‐X and Denosumab in Healthy Adult Males
  di: Emmanuel Biver, et al.
  Pubblicazione: (2026)